Skip to main content

Advertisement

Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers—results of a dose escalation trial

Fig. 3

Mobilization of immature hematopoietic cells: comparison with G-CSF. Baseline circulating CD34+ cells, balixafortide mobilized CD34+ cells (incremental balixafortide dose as indicated on X-axis) and G-CSF mobilized CD34+ cells (same G-CSF dose for all groups, see “Methods” section) are displayed in (a). Corresponding fold-increase data are shown in (b). Symbols represent individual values, the short horizontal bar and whiskers mean ± SEM. n = 3–6. c Intra-individual comparison of peak mobilization with 1000 vs. 2500 µg/kg (left panel, n = 3) or 1500 vs. 2500 µg/kg (right panel, n = 6) of balixafortide is shown. 2500 µg/kg balixafortide mobilized more CD34+ cells than 1000 µg/kg, whereas no difference between peak mobilization with 1500 vs. 2500 µg/kg was observed. Symbols represent individual values. d The good correlation between effectiveness of G-CSF vs. balixafortide with respect to CD34+ cell mobilization is displayed for balixafortide doses between 1500 and 2500 µg/kg n = 14. Symbols represent individual values (constant rate only)

Back to article page